Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Background The pharmacokinetics and appropriate dose regimens of favipiravir are unknown in hospitalized influenza patients; such data are also needed to determine dosage selection for favipiravir trials in COVID-19. Methods In this dose-escalating study, favipiravir pharmacokinetics and tolerabili...

Full description

Bibliographic Details
Main Authors:	Wang, Y, Zhong, W, Salam, A, Tarning, J, Zhan, Q, Huang, J-A, Weng, H, Bai, C, Ren, Y, Yamada, K, Wang, D, Guo, Q, Fang, Q, Tsutomu, S, Zou, X, Li, H, Gillesen, A, Castle, L, Chen, C, Zhen, J, Lu, B, Duan, J, Guo, L, Jiang, J, Cao, R, Fan, G, Li, J, Hayden, FG, Wang, C, Horby, P, Cao, B
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

Similar Items